Trial Profile
Evaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX13-608 in the treatment of relapsed or refractory multiple myeloma: a multicenter, open label, dose-escalation, phase I clinical trial
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs CX-13-608 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Ningbo Shengjian Biomedical Technology
- 18 Jul 2018 New trial record